Danaher Corporation · DHR · Next earnings

Danaher Corporation reports Tuesday, Oct 20, 2026

DHR reports before market open with consensus EPS at $1.91 and revenue at $6.55B. Last quarter: Danaher Q2 Beats EPS and Revenue, Raises FY Guidance; Bioprocessing Shipment Delays Pressure Stock

Reports Before market open30 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.91 Calendar consensus
Consensus revenue $6.55B Calendar consensus
Report date Oct 20, 2026 Tuesday, date estimated
Session Before market open 30 days away

Where DHR left off: FY2026 Q2

Full report

Danaher Q2 Beats EPS and Revenue, Raises FY Guidance; Bioprocessing Shipment Delays Pressure Stock

EPS surprise +4.9% Reported $1.94 vs $1.85
Revenue surprise +2.4% Reported $6.26B vs $6.12B
Stock move -11.0% Event window
Subsequent drift +11.2% Up to 20 sessions

Full-year adjusted EPS guidance raised from $8.35–$8.55 (Q1 midpoint $8.45) to $8.45–$8.60 (Q2 midpoint $8.525), an increase of approximately $0.08 at the midpoint. Guidance sentiment: raised. Management expressed confidence in the trajectory supported by the Masimo contribution, new product launches, and continued bioprocessing demand.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Bioprocessing shipment timing delays may continue to pressure near-term revenue conversion
  • Respiratory testing headwinds affecting quarterly growth
  • Continued weakness in academic and government funding markets
  • Regulatory approval timing for new assays and devices
  • Integration risk associated with Masimo and StatLab acquisitions

Questions analysts left open

  • Visibility and timing of bioprocessing consumables revenue
  • Magnitude and duration of respiratory testing headwinds
  • Progress and timing of Masimo integration
  • Academic and government market recovery outlook
  • Assumptions underlying full-year growth guidance

Ask FN2 about DHR next report

Transcript, numbers and history already loaded
What should I watch for in DHR's next earnings report?How did DHR guide last quarter, and is consensus above or below that?Give me the bull and bear case going into DHR earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the DHR recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent DHR quarters

All DHR earnings
-11.0%FY2026 Q2

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.